MedPath

A study of onabotulinum toxin type A for the treatment of ultraviolet B-induced hyperpigmentation: a prospective, randomized, controlled trial

Phase 3
Completed
Conditions
VB-induced hyperpigmentation
UVB, hyperpigmentation, onabotulinum toxin
Registration Number
TCTR20211111002
Lead Sponsor
Division of Dermatology, Department of medicine, Faculty of Medicine, Ramathibodi hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
15
Inclusion Criteria

Healthy subjects older than 18-year-old

Exclusion Criteria

the subjects who have the serious underlying diseases, pregnancy, active skin diseases, allergic reaction to BoNT-A, history of photosensitive disorders, and ongoing use of topical medications or laser procedures at the experimental sites

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
mean lightness index 0, 7, 21, 28, 35-week colorimeter
Secondary Outcome Measures
NameTimeMethod
improvement score 35-week blinded physician
© Copyright 2025. All Rights Reserved by MedPath